Carregant...
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of PARP inhibitors is based on the DNA repair vulnerability of many ovarian cancer cells, and multiple mechanisms of action o...
Guardat en:
| Publicat a: | Ther Adv Med Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5405993/ https://ncbi.nlm.nih.gov/pubmed/28491146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016687254 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|